Monday sell-off: Another ASX 300 director goes on a bargain share-buying spree

This ASX 300 healthcare director is taking advantage of today's weakness.

| More on:
Three people in a corporate office pour over a tablet, ready to invest.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The PolyNovo share price has been caught up in the wider market sell-off today 
  • But one of the company's directors has taken advantage of this weakness 
  • PolyNovo shares are still sitting in the green this year 

The PolyNovo Ltd (ASX: PNV) share price is coming under pressure today as the S&P/ASX 300 Index (ASX: XKO) faces another sea of red.

At the time of writing, the PolyNovo share price has slid 5.7% to last change hands at $1.65 apiece.

Meanwhile, the ASX 300 index has slipped by 1.6% to 6,640 points.

But one PolyNovo director is seeing this weakness as an opportunity to pick up more shares. Let's take a look.

PolyNovo chair pounces

Through an ASX release, we learned that PolyNovo chair David Williams has been on a share-buying spree today.

He's indirectly purchased 115,000 PolyNovo shares on-market at an average price of $1.7231, splashing nearly $200,000 in the process.

Today's purchase takes Williams' total shareholding to 24.7 million PolyNovo shares, which are worth around $41 million at current prices. He owns roughly 3.7% of the company.

This isn't the first time Williams has picked up PolyNovo shares this year. He went on a major buying spree in May and June, indirectly acquiring roughly 5.7 million PolyNovo shares on-market. He did so across 18 transactions, scooping up PolyNovo shares at average prices ranging from $0.87 to $1.27. 

These moves have since proven to be savvy, with the PolyNovo share price sitting comfortably above these levels today.

Williams is a long-serving member of PolyNovo's board, having first been appointed in 2014. He is also chair of fellow ASX healthcare share Medical Developments International Ltd (ASX: MVP), in which he owns 10.7 million shares.

Recent trading update

Today's director buying is hot on the heels of a first-quarter trading update from PolyNovo last week.

The company achieved its first-ever $5 million sales month, raking in $5.4 million in September. Across the first quarter, the company achieved record September quarter sales of $12.5 million, up 73% from $7.2 million in the prior corresponding period (pcp).

PolyNovo noted that growth accelerated in the US, delivering record quarterly sales of $10.4 million, up 71% from the pcp. Meanwhile, rest of world sales grew by 84% to $2.1 million.

PolyNovo share price snapshot

Despite today's slump, PolyNovo is one of the rare ASX 300 shares sitting in the green this year. 

The PolyNovo share price has gained 8% in the year to date. But zooming in to the last six months, PolyNovo shares have shot the lights out with a 57% gain.

The last month also tells a positive tale, with the PolyNovo share price racing 17% higher.

PolyNovo shares fell out of the S&P/ASX 200 Index (ASX: XJO) in the June rebalance earlier this year. The ASX 300 healthcare company currently commands a market capitalisation of around $1.1 billion.

Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Medical Developments International Limited and POLYNOVO FPO. The Motley Fool Australia has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »